Statement: 1 patient in the primary trial was affected by Sepsis.
Primary_evidence: Adverse Events 1:   Total: 17/40 (42.50%)   Anaemia 2/40 (5.00%)   Febrile Neutropenia 3/40 (7.50%)   Neutropenia 2/40 (5.00%)   Thrombocytopenia 5/40 (12.50%)   Pericardial Effusion 1/40 (2.50%)   Abdominal Pain Lower 1/40 (2.50%)   Disease Progression 6/40 (15.00%)   Fatigue 1/40 (2.50%)   Pyrexia 3/40 (7.50%)   Septic Shock 1/40 (2.50%)   Streptococcal Infection 1/40 (2.50%)